A therapeutics platform for curing inflammatory disorders
Company research
Public company, workplace, funding, and market signals
Overview
Boston-based biotech founded in spring 2021 that is developing non-immunosuppressive, oral, bacterial-molecule-inspired therapies to restore immune balance and treat inflammatory diseases, starting with Crohn’s disease.
Primary product
An oral, bowel-specific small-molecule immunomodulatory therapy for Crohn’s disease and other inflammatory diseases
Founded
2021
Headquarters
Boston, Massachusetts, United States; Pagliuca Harvard Life Lab, 127 Western Avenue, Allston, MA 02134-1008
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Inflammatory disease therapeutics
Offices
Pagliuca Harvard Life Lab, 127 Western Avenue, Allston, MA 02134-1008, Allston, MA, United States
Boston / Allston, Massachusetts, United States
Business model
drug discovery
drug development
platform therapeutics
Funding
Stage
Seed
Total raised
$2.4M
Latest round
Seed · Jan 2022
Latest amount
$2.2M
Harvard President's Innovation Challenge award
May 2026 · Harvard Innovation Labs
Feb 2024 · Propel a Cure for Crohn's Disease
Nov 2023 · National Institute of Diabetes and Digestive and Kidney Diseases
Jan 2022
Aug 2021 · PROTOCOL — by GETTYLAB
Mar 2021 · Allston Venture Fund
Massachusetts Life Sciences Center
People & investors
Leadership
Founder & CEO
Co-founder, Chief Scientific Officer, Secretary
Investors
Allston Venture Fund
Angel investors
Asymmetry Ventures
Harvard Innovation Labs
Harvard Venture Incubation Program
Large biotech funds
Massachusetts Life Sciences Center
Metaplanet
National Institute of Diabetes and Digestive and Kidney Diseases
Pioneer Fund
Propel a Cure for Crohn's Disease
PROTOCOL — by GETTYLAB
Y Combinator
ZAKA Ventures
Work & culture
Entrepreneurial, science-driven, and translational; the company describes its team as entrepreneurs, scientists, and drug discovery professionals and emphasizes thinking differently and pursuing unconventional approaches.
Product & market
Differentiators
- —non-immunosuppressive approach
- —aims to restore immune balance rather than block the immune system
- —oral and bowel-specific delivery focus
- —root-cause treatment philosophy
- —bacterial-molecule-inspired mechanism
- —patient-sample-informed discovery
- —single-cell and computational profiling support
Technology
patient-sample-driven discovery
small-molecule immunomodulators
oral drug candidate development
single-cell gene expression profiling
computational analysis
rodent disease models
pharmacodynamics assays
bacterial-molecule-inspired therapeutics
Customers
patients with Crohn’s disease
patients with chronic inflammatory diseases
patients with autoimmune/autoinflammatory diseases
Competitors
standard immunosuppressive Crohn’s/IBD therapies
anti-TNF biologics
IL-23 / IL-17 pathway therapies
JAK inhibitors
other early-stage IBD and inflammation drug developers
Scale & contact
Jobs and careers at Promakhos Therapeutics
0 jobs at Promakhos Therapeutics
No open positions
Check back later for new openings